Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort.
about
Preoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomyAdditive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cellsMetabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients.Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancerMeasurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyAnthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.
P2860
Q28546623-169FD532-8A52-4657-ACEA-860004688D64Q33715022-D9C67563-426D-43F2-B341-F84DE6910CCAQ34786457-59718BA1-5F0D-43BD-AA09-CE76538C0A1CQ36272043-10DB0695-5090-4DCC-815C-D42857603173Q36327268-4B9FDE82-F48A-4E11-A8E7-ADACFB9FAFEEQ36657326-B343CD0C-2131-4C6C-B22D-7C0751A8D8DDQ37120159-DAC4A60B-79AF-4B0C-9A13-5B63EA59510DQ38717505-E0CF8FA6-B726-4AA1-86BC-7F917431314FQ38764762-177CF6CE-CA92-48DA-BA0F-22A05CC5FDF6Q41630845-1B854614-4935-4069-8DD2-325E92FFC947Q51310879-7A5A7032-AAE5-429D-A0FE-80BE05155E20Q52911366-67DE2732-7A10-473C-A49D-0D4BAF985D79
P2860
Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Fasting glucose and treatment ...... esults from a historic cohort.
@ast
Fasting glucose and treatment ...... esults from a historic cohort.
@en
type
label
Fasting glucose and treatment ...... esults from a historic cohort.
@ast
Fasting glucose and treatment ...... esults from a historic cohort.
@en
prefLabel
Fasting glucose and treatment ...... esults from a historic cohort.
@ast
Fasting glucose and treatment ...... esults from a historic cohort.
@en
P2093
P2860
P50
P356
P1433
P1476
Fasting glucose and treatment ...... results from a historic cohort
@en
P2093
C Carlomagno
G Delle Fave
M Montella
M Mottolese
P2860
P304
P356
10.1093/ANNONC/MDR540
P50
P577
2011-11-18T00:00:00Z